266 related articles for article (PubMed ID: 22674438)
21. Prognostic impact of gastrointestinal bleeding and expression of PTEN and Ki-67 on primary gastrointestinal stromal tumors.
Wang H; Chen P; Liu XX; Zhao W; Shi L; Gu XW; Zhu CR; Zhu HH; Zong L
World J Surg Oncol; 2014 Apr; 12():89. PubMed ID: 24712384
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
Ahlgren GM; Flodgren P; Tammela TLJ; Kellokumpu-Lehtinen P; Borre M; Angelsen A; Iversen JR; Sverrisdottir A; Jonsson E; Sengelov L;
Eur Urol; 2018 Jun; 73(6):870-876. PubMed ID: 29395502
[TBL] [Abstract][Full Text] [Related]
23. p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer.
Vlachostergios PJ; Karasavvidou F; Patrikidou A; Voutsadakis IA; Kakkas G; Moutzouris G; Zintzaras E; Daliani DD; Melekos MD; Papandreou CN
Pathol Oncol Res; 2012 Apr; 18(2):245-52. PubMed ID: 21786090
[TBL] [Abstract][Full Text] [Related]
24. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.
Tretiakova MS; Wei W; Boyer HD; Newcomb LF; Hawley S; Auman H; Vakar-Lopez F; McKenney JK; Fazli L; Simko J; Troyer DA; Hurtado-Coll A; Thompson IM; Carroll PR; Ellis WJ; Gleave ME; Nelson PS; Lin DW; True LD; Feng Z; Brooks JD
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):264-70. PubMed ID: 27136741
[TBL] [Abstract][Full Text] [Related]
26. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy.
Bauer JJ; Connelly RR; Sesterhenn IA; Bettencourt MC; McLeod DG; Srivastava S; Moul JW
Cancer; 1997 Mar; 79(5):952-62. PubMed ID: 9041158
[TBL] [Abstract][Full Text] [Related]
27. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
28. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer.
Bubendorf L; Tapia C; Gasser TC; Casella R; Grunder B; Moch H; Mihatsch MJ; Sauter G
Hum Pathol; 1998 Sep; 29(9):949-54. PubMed ID: 9744310
[TBL] [Abstract][Full Text] [Related]
29. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Factors of Prostate Cancer in Tunisian Men: Immunohistochemical Study.
Missaoui N; Abdelkarim SB; Mokni M; Hmissa S
Asian Pac J Cancer Prev; 2016; 17(5):2655. PubMed ID: 27268646
[TBL] [Abstract][Full Text] [Related]
31. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
32. [p53 and Ki67 expression in specimens of radical prostatectomy. Relationship with clinico-pathologic data and survival].
Zudaire Bergera JJ; Sánchez Zalabardo D; Arocena García-Tapia J; Sanz Pérez G; Díez Caballero F; López Ferrandis J; Rosell Costa D; Robles García JE; de Alava E; Berián Polo JM
Actas Urol Esp; 2000 Apr; 24(4):307-13. PubMed ID: 14964088
[TBL] [Abstract][Full Text] [Related]
33. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
[TBL] [Abstract][Full Text] [Related]
34. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
Tosoian JJ; Almutairi F; Morais CL; Glavaris S; Hicks J; Sundi D; Humphreys E; Han M; De Marzo AM; Ross AE; Tomlins SA; Schaeffer EM; Trock BJ; Lotan TL
Eur Urol; 2017 May; 71(5):697-700. PubMed ID: 27477529
[TBL] [Abstract][Full Text] [Related]
36. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy.
Wu TT; Wang JS; Lu CM; Lee YH; Huang JK
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923
[TBL] [Abstract][Full Text] [Related]
37. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT
J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984
[TBL] [Abstract][Full Text] [Related]
38. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
39. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
[TBL] [Abstract][Full Text] [Related]
40. Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.
Hegde JV; Veruttipong D; Said JW; Reiter RE; Steinberg ML; King CR; Kishan AU
Urology; 2017 Sep; 107():171-177. PubMed ID: 28552819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
